FDA Qualification process – Drug Development Tools

Published by IRDiRC

Animal Model Biomarker Center for Drug Evaluation and Research Clinical Development Drug Development Tool Endpoint Qualification Process Regulatory Affairs Research and Drug Development

This guidance provides a framework for interactions between the Center for Drug Evaluation and Research (CDER) and the entity proposing the DDT for qualification (the submitter). It also explains the kinds of data that should be submitted to support qualification of a DDT and creates a mechanism for CDER’s formal review of the data to ultimately qualify the DDT.

View this resource Bookmark this resource

Consultations on Pharmacogenomics / Biomarkers (As part of PMDA consultations)

Published by IRDiRC

Biomarker Early Access Support MHLW or PMDA Regulatory Pharmacogenomics PMDA Regulatory Affairs Scientific Advice

Consultations on Pharmacogenomics / Biomarkers is one of the PMDA consultations. The purpose of this consultation is to provide general scientific advice for utilization of pharmacogenomics or biomarkers that are not specified in a certain product.

View this resource Bookmark this resource

Tissue Chip for Drug Screening program and Consortium

Published by IRDiRC

Biomarker Drug Discovery Drug Screening Programme High Throughput Screening Library NCATS Research and Drug Development Tissue Chip

NCATS, in collaboration with other NIH Institutes and Centers and the Food and Drug Administration (FDA), is leading the Tissue Chip for Drug Screening program to develop human tissue chips that accurately model the structure and function of human organs — such as the lungs, liver and heart — to help predict drug Safety in humans more rapidly and effectively

View this resource Bookmark this resource

Development and use of Patient-Centered Outcome Measures

Published by IRDiRC

Biomarker Clinical Development Endpoint Patient-Centred Outcome Measure Research and Drug Development

Patient-Centred Outcomes Measures (PCOMs) are questionnaires that ‘directly’ quantify the impact of a disease and treatment on health outcomes that matter to patients (as identified or affirmed by patients themselves, or their caregivers)

View this resource Bookmark this resource

The Innovation Management Toolbox was originally developed through funding from the EJP RD project, which received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825575. The continued development and maintenance of the Toolbox are now supported by the ERDERA partnership, funded under the European Union’s Horizon Europe Research & Innovation programme, grant agreement No. 101156595.

IMT Feedback

Did the IMT help you in finding the resource you needed?